# Tirzepatide Works Just as Well and as Safely for Adults Over 65

*Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.*

- **Evidence Level**: Moderate
- **Publication Types**: Journal Article
- **Journal**: Diabetes, obesity & metabolism
- **Sample Size**: Adults with obesity from Phase 3 trials, comparing those 65+ vs under 65
- **Authors**: Alfaris N, Kushner RF, Li J, Chen KL, Fenimore M, Calderon B, Stefanski A
- **Published**: 2026-06-16
- **Topics**: GLP-1, weight loss, healthy aging
- **DOI**: https://doi.org/10.1111/dom.70991
- **Original Source**: https://pubmed.ncbi.nlm.nih.gov/42303274/

## Summary

Tirzepatide is the popular GLP-1 weight loss drug also sold as Mounjaro and Zepbound. This look back at big trials found it helped adults over 65 lose weight and improve heart and blood sugar health. The benefits and side effects matched what younger adults saw, with no new risks for older bodies.

## Practical Takeaway

This analysis suggests tirzepatide may be a reasonable weight option for older adults after weighing risks.

---

_Canonical: https://longevity-china.com/en/research/tirzepatide-works-just-as-well-and-as-safely-for-adults-over-65 · Part of Longevity Cities · Updated 2026-06-16_